Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 949-956

  Marteau, P ^a,b   Nelet, F ^a   Le Lu, M ^a   Devaux, C ^c  

^a Ferring SAS   (France)

^b Hopital Saint Lazare   (France)

^c Ferring Product Development   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADVERSE DRUG REACTION; ARTICLE; BLOOD DYSCRASIA; CARDIOTOXICITY; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; FRANCE; HUMAN; LIVER TOXICITY; MYOCARDITIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PANCREATITIS; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0029799045     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.92264000.x     Document Type: Article

References (83)

1. Hanauer SB, Kirsner JB. Medical therapy in ulcerative colitis. In: Kirsner JB, Shorter RG eds. Inflammatory Bowel Disease, 3rd edn. Philadelphia, Pennsylvania: Lea Fibiger, 1988: 431-75.
2. Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 1427-33.
3. Hanauer S, Krawitt E, Robinson M, et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Am J Gastroenterol 1993; 88: 1343-52.
4. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188-97.
5. Singleton J, Hanauer S, Gitnik G, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293-301.
6. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9.
7. Meyers S, Sachard DB, Present DH, Janowitz HD. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Scand J Gastroenterol 1988; 23: 29-37.
8. Segars LW, Gales BJ. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Clin Pharmacol 1992; 11: 514-28.
9. Dew MJ, Harries AD, Evans BK, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulfasalazine. Lancet 1983; ii: 801.
10. Turunen U, Elomaa I, Anttila VJ, Seppala K. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol 1987; 22: 798-802.
11. Habal FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Am J Gastroenterol 1988; 83: 15-9.
12. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987; 22: 332-6.
13. Anonymous. Bonnes pratiques de pharmacovigilance. Saint-Denis: Mínistère des Affaires Sociales, de la Santé et de la Ville, Agence du Médicament, 1994.
14. World Health Organization. Guidelines for preparing low clinical safety. Information on drugs/Reports of CIOMS. WG III 1995.
15. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985; 40: 111-8.
16. Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994; 344: 620-1.
17. Goodman S, Gilman A. The Pharmacological Basis of Therapeutics, 5th edn. New York: Macmillan, 1979.
18. Jenss H, Weber P, Hartmann F. 5-aminosalicylic acid and its metabolite in breast milk during lactation. Am J Gastroenterol 1990; 85: 331.
19. Järnerot G, Into-Malmberg MB, Esbjörner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16: 693-7.
20. Christensen LA, Rasmussen SN, Honore Hansen S, Bondesen S, Hvidberg EF. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand 1987; 66: 433-5.
21. Hautekeete ML, Bourgeois N, Potvin P. et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 1992; 103: 1925-7.
22. Lesur G, Saveuse H, Legros V, et al. Eruption cutanée et pneumopathie d'hypersensibilité au cours d'un traitement par le 5-aminosalicylate. Gastroenterol Clin Biol 1991; 15: 457.
23. Brimblecombe R. Mesalazine: a global safety evaluation. Scand J Gastroenterol 1990; 25: 66-8.
24. Finnic IA, Gilmore IT. Skin rash, fever and rigors caused by olsalazine. Eur J Gastroenterol Hepatol 1993; 5: 881-3.
25. Lim AG, Hine KR. Fever, vasculitis rash, arthritis, pericarditis, and pericardial effusion after mesalazine. Br Med J 1994; 308: 113.
26. Alstead EM, Wilson AGMCT. Farthing MJG. Lichen planus and mesalazine. J Clin Gastroenterol 1991; 13: 335-7.
27. Dent M, Ganapathy S, Holdsworth C, Channer K. Mesalazine induced lupus-like syndrome. Br Med J 1992; 305: 159.
28. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42.
29. Kutty PK, Raman KRK, Hawken K, Barrowman JA. Hair loss and 5-aminosalicylic acid enemas. Ann Intern Med 1982; 97: 785-6.
30. Modigliani R, Rambaud JC. Les nouveaux dérivés de la Salazosulfapyridine. Un progrès dans le traitement des maladies inflammatoires chroniques de l'intestin. Gastroenterol Clin Biol 1987; 11: 325-32.
31. Järnerot G. Clinical tolerance to olsalazine. Scand J Gastroenterol 1988; 23 (Suppl. 148): 21-3.
32. Hadjigogos K. Unusual side effects of mesalazine. Ital J Gastroenterol 1991; 23: 257.
33. Waanders H, Thompson J. Kawasaki-like syndrome after treatment with mesalazine. Am J Gastroenterol 1991; 86: 219-21.
34. Honeybourne D. Mesalazine toxicity. Br Med J 1994; 308: 533-4.
35. Bodin F, Biour M, Grange JD. Leucopénie au décours de la prise de sulfasalazine puis de mésalazine chez un même patient. Therapie 1991; 46: 341.
36. Wyatt S, Joyner MV, Daneshmend TK. Filgrastim for mesalazine-associated neutropenia. Lancet 1993; 341: 1476.
37. Abboudi ZH, Marsh JCW, Smith-Laing G, Gordon-Smith EC. Fatal aplastic anaemia after mesalazine. Lancet 1994; 343: 542.
38. Daneshmend TK. Mesalazine-associated thrombocytopenia. Lancet 1991; 337: 1297-8.
39. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol 1990; 2: 198-9.
40. Committee on Safety of Medicine. Sulfasalazine and fatal blood dysazasias. Curr Probl Pharmacovigilance 1993; 19: 6.
41. Committee on Safety of Medicine. Blood dyscrasias and mesalazine. Curr Probl Pharmacovigilance 1995; 21: 314.
42. Winther K, Bondesen S, Honore Hansen S, Hvidberg EF. Lack of effects of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro. Eur J Clin Pharmacol 1987; 33: 419-22.
43. Raimundo A, Patil D, Frost P, Silk D. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991; 32: 270-4.
44. Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993; 88: 1684-98.
45. Sturgeon JB, Bhatia P, Hermens D, Miner PB. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 1995; 108: 1889-93.
46. Kapur KC, Williams GT, Allison MC. Mesalazine induced exacerbation of ulcerative colitis. Gut 1995; 37: 838-9.
47. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, De La Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990; 35: 1180-2.
48. Tran K, Froguel E, Jian R, Lemann M, Modigliani R. Acute pancreatitis induced by mesalazine. J Clin Gastroenterol 1991; 13: 715-6.
49. Radke M, Bartolomaeus G, Muller M, Richter I. Acute pancreatitis in Chron's disease due to 5-ASA therapy. J Pediat Gastroenterol Nutr 1993; 16: 337-9.
50. Garau P, Orenstein SR, Neigut DA, Kocoshis SA. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 18: 481-5.
51. Tromm A, Huppe D, Micklefield GH, Schwegler U, May B. Acute pancreatitis complicating Crohn's disease: mere coincidence or causality? Gut 1992; 33: 1289-91.
52. Biour R, Poupon R, Grangé JD, et al. Hépatotoxicité des médicaments: 7ème mise à jour du fichier bibliographique des atteintes hépatiques et des médicaments responsables. Gastroenterol Clin Biol 1994; 18: 574-606.
53. Pineda JR, Leal JC, De La Morena E, Abreu L. Hepatotoxicidad: un efecto secundario nuevo del acido 5-aminosalicylico. Med Clin (Barc) 1989; 93: 516.
54. Mulder H, Gratama S. Azodisalicylate (Dipentum)-induced hepatitis? J Clin Gastroenterol 1989; 11: 708-11.
55. Rachmilewitz D. Coated mesalazine ( 5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82-6.
56. Marteau P, Halphen M. Etude comparative randomisée de l'efficacité et de la tolerance de lavements de 2 g d'acide 4-amino-salicylique (4-ASA) et de 1 g d'acide 5-amino-salicylique (5-ASA) dans les formes basses de rectocolite hémorragique. Gastroenterol Clin Biol 1995; 19: 31-5.
57. Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol 1990; 25: 52-5.
58. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-9.
59. Committee on Safety of Medicines. Nephrotoxicity associated with mesalazine (Asacol). Curr Probl Pharmacovigilance 1990; 30: 2.
60. Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992; 33: 563-4.
61. Tuluvulath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-6.
62. Smilde TJ, Van Liebergen FJHM, Koolen MI. et al. Tubulo-interstitiële nefritis door mesalazine (5-ASA)-preparaten. Ned Tijdschr Geneeskd 1994; 138: 2557-61.
63. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-52.
64. Bonnet J, Lemann M, Prunat A, et al. Renal function in patients with inflammatory bowel disease (IBD) on long-term mesalazine (Mz) or olsalazine (Oz). Gastroenterology 1995; 108: A786. (Abstract.)
65. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine 1993; 72: 151-83.
66. Weber P, Becker EW, Jenss H. Perikarderguß während der Therapie eines Morbus Crohn mit 5-Aminosalicylsäure. Dtsch Med Wochenschr 1988; 113: 1806-7.
67. FDA. Rare adverse reaction with rowasa. FDA Drug Bull 1989; 19: 17-8.
68. Jenss H, Becker EW, Weber P. Pericardial effusion during treatment with 5-aminosalicylic acid in a patient with Crohn's disease. Am J Gastroenterol 1990; 85: 332-3.
69. Heresbach D, Rabot A, Génetet N, et al. Péricardite au cours des maladies inflammatoires intestinales. Complication extra-intestinale ou iatrogène? Gastroenterol Clin Biol 1994; 18: 782-5.
70. Desmeules J, Vogt N, Loizeau S, Angelillo-Scherrer A, Dayer P. Péricardite récidivante induite par la mesalazine (5-ASA). Therapie 1994; 49: 359-61.
71. Agnholt J, Sorensen HT, Rasmussen SN, Gotzsche CO, Halkier P. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989; ii: 1135.
72. Kristensen KS, Hoegholm A, Bohr L, Friis S. Fatal myocarditis associated with mesalazine. Lancet 1992; 335: 605.
73. Weite T, Hamm H, Fabel H. Mesalazine alveolitis. Lancet 1991; 338: 1273.
74. Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalazine for ulcerative colitis. Chest 1992; 101: 1469-71.
75. Woodward DK. Peripheral neuropathy and mesalazine. Br Med J 1989; 299: 1224.
76. Cann PA, Holdsworth CD. Reversal of male infertility on changing treatment from sulfasalazine to 5-aminosalicylic acid. Lancet 1984; i: 1119.
77. Shaffer JL, Kershaw A, Berrisford MH. Sulfasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet 1984; i: 1240.
78. Chatzinoff M, Guarino JM, Corson SL, Batzer FR, Friedman LS. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. Dig Dis Sci 1988; 33: 108-10.
79. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy : safety and clinical course. Gastroenterology 1993; 105: 1057-60.
80. Trallori G. D'Albasio G, Bardazzi G, et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994; 26: 75-8.
81. Jonville Bera AP, Soyez C, Fignon A, et al. Pentasa (mesalazine) et grossesse. Therapie 1994; 49: 443-5.
82. Marteau P, Crand J, Devaux C. Mesalazine in pregnancy: fetal outcome in 76 IBD patients treated with Pentasa. Gastroenterology 1995; 108: A871 (Abstract).
83. Marteau P, Devaux C. Mesalazine during pregnancy. Lancet 1994; 344: 1708-9.